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Sllmmal'y 
Interleukin 1 (IL-1) plays a central role in the regulation of the body's response to infectious 
and inflammatory stimuli. Recent evidence has shown that human platelets express a cell associated 
form of this proinflammatory cytokine very rapidly following activation. Since one of the earliest 
events in inflammation is frequently the rapid adhesion of platelets  to injured endothelium, it 
was of interest to determine whether platelets express IL-1 in a functionally relevant form that 
can alter the phenotype of human endothelial cells in vitro. Thrombin activated platelets induced 
significant expression of the adhesion molecule intercellular adhesion molecule 1, as well as secretion 
of the IL-1 inducible cytokines Ib6 and granulocyte macrophage colony stimulating factor by 
cultured human umbilical cord and saphenous vein endothelial cells. This was inhibited by prior 
treatment of the platelets with antibody specific  for Ibl, These results suggest that platelet delivered 
IL-1 might initiate and regulate some of the earliest  phases of the inflammatory response.  An 
additional observation of interest was differential  induction of endothelial leucocyte adhesion 
molecule I by activated platelets on saphenous vein but not umbilical vein endothelial cells, which 
suggests functional heterogeneity of the endothelial cells. 
T 
he vascular endothelium normally maintains a throm- 
boresistant luminal surface but following injury there 
is a rapid loss of this anticoagulant state, with consequent 
platelet binding and activation (1, 2). Endothelial cells also 
play an important role in the inflammatory response, where 
they undergo significant  functional changes.  These include 
increased expression of adhesion promoting molecules such 
as intercellular adhesion molecule-1 (ICAM-1) 1 and endo- 
thelial leucocyte adhesion molecule-1 (ELAM-1), thus leading 
to the binding and extravasation of leukocytes, as well as the 
release of soluble mediators (3, 4).  Many of these changes 
can be mimicked in vitro by the addition of recombinant 
cytokines such as IL-1 and TNF to endothelial cell monolayers 
(5, 6). In addition local injection of Ibl or TNF results in 
rapid recruitment of leukocytes from the blood (7, 8), and 
these cytokines can be detected at sites of inflammatory le- 
sions, e.g., autoimmune sites and atherosclerotic lesions (9-11). 
These studies predict an important role for such cytokines 
in vivo in controlling the phenotype and function of en- 
dothelial and other inflammatory cells at sites of inflamma- 
1  Abbreviations  used in this paper: ADP, adenosine diphosphate; ELAM-1, 
endothelial  leukocyte adhesion molecule  1;  GM-CSF, granulocyte 
macrophage colony-stimulating factor; HUVEC, human umbilical vein; 
ICAM-1, intercellular adhesion molecule 1; SAVEC,  adult saphenous vein. 
tion and immunological challenge. However the source and 
regulation of their production at the site of injury, especially 
in its earliest stages prior to leucocytic adherence and extrava- 
sation, has not been dearly identified. 
One of us (C. M. Hawrylowicz) has recently demonstrated 
that following activation, human platelets are rapidly induced 
to express a cell associated form of the cytokine Ibl (12). 
Agonists that stimulate its expression in vitro include aden- 
osine diphosphate (ADP), collagen and thrombin, which are 
known to be present at sites of injury. Based on the impor- 
tance of II.,1 in modulating endothelial function both in vitro 
and in vivo (5-8), we have now examined whether platelet 
derived II.-1 is present in a functionally relevant form that 
might thus provide an important early signal for the activa- 
tion of the endothelium at sites of inflammation. 
Materials and Methods 
Plateletpre~ration.  Washed  platdets were prepared  from freshly 
drawn venous blood  treated with  1/10 volume of citrate an- 
ticoagulant as previously  described  (12). Hatelet preparations were 
contaminated with less than 0.1% red blood cells and no obvious 
(less than 0.01%) mononuclear cell contamination was observed. 
Washed platelet preparations were activated with 0.5-1 U/ml 
thrombin prepared  from human plasma (Sigma  Chemical  Co., Poole, 
UK) for 2-4 min at room temperature. 
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from umbilical vein or adult saphenous vein by collagenase  diges- 
tion as previously  described  (13), and grown on RPMI-1640 medium 
supplemented with 15-30/~g/ml endothelial growth factor (Sigma 
Chemical Co., 50 U/ml sodium hepafin and 10% newborn (NBS) 
plus 10% FCS. Calls were routinely used between the second and 
fifth passages. 
1 or 2 d before an experiment endothelial cells were plated on 
gelatin coated 24-well microtiter plates at a density of  approximately 
5 x  104  -  10  s cells per well. Immediately before stimulation en- 
dothelial monolayers  were washed 2-3 times in prewarmed serum 
free medium. Fig. 1 A demonstrates  the purity of  endothelial  prepa- 
rations by staining with two markers for endothelial surface an- 
tigens, antibody specific  for gplla (CLB-HEC75; a kind gift from 
Dr. J.A. van Mourik, Central Laboratory of the Netherlands Red 
Cross Blood Transfusion,  Amsterdam, The Netherlands) and Ulex 
Europaeus-1 lectin coupled to fluorescein isothiocyanate (ULEX- 
FITC; Sigma Chemical Co.). 
Endothelial Cell Stimulation.  Endothelial  cells were cultured with 
2-5  x  107 resting or thrombin  activated platelets, superuatant 
from an equivalent number of activated platelets, thrombin (at a 
final  concentration of 0.05-0.1 U/ml, and comparable to that added 
in the activated  platelet preparations), the indicated concentrations 
of ri1r  (specific activity 1.6  x  108 U/mg, kindly provided by 
Dr. P. Lomedico, Hoffman La Roche, Nutley, N.J.), or medium 
alone for 6-24 h at 37~  in a 5% CO2 humidified atmosphere 
in a final volume of I  ml RPMI-1640 with 10-15% FCS. 
Anti-Cytokine Antibodies.  In the experiments described in Fig. 
1 C and 3 B and/3, mouse mAb to human Iblc~ (Dai Nippon, 
Japan; IgG1) was used at 4 #g/ml and goat antiserum specific  for 
human IDIB at a dilution of 1:800 (Immunex Corporation, Seattle, 
WA). Control irrelevant antibodies used were a 1:800 dilution of 
normal goat serum (Sigma  Chemical  Co.) and 5/zg/ml monoclonal 
mouse anti-human TNF (TNF-E, Genentech; IgG1). In Fig. 2 B 
a 1:100 dilution of polyclonal rabbit antiserum specific for Ibl~, 
IL-I~, or a combination of  both (kindly donated by Immunex Cor- 
poration) were used to pretreat activated platelets before the addi- 
tion to endothelial cell stimulation cultures and giving a final in- 
dividual serum concentration of 1/1,000 in culture. Alternatively, 
polyclonal  rabbit antiserum specific  for Ib4 (used at 20/~g/ml) final 
concentration, Immunex Corporation) were used as control. Ad- 
ditional control antibodies used included goat antiserum specific 
for human II+-6 (kindly provided by Dr. L. Aarden, Central Labo- 
ratory of  the Netherlands  Red Cross Blood  Transfusion,  Amsterdam, 
The Netherlands) and rabbit antiserum to human transforming 
growth factor beta (TGFB) generated in this laboratory by Dr. E. 
Abney. 
Immunostaining.  Following culture endothelial cells were ex- 
tensively  washed in prewarmed HBSS and incubated with versene 
for 15-30 rain at 37~  at which time they detached readily from 
the tissue culture plate, and were washed twice. Cells (approxi- 
mately 10  s per group) were stained for ICAM-1 expression with 
a 1:1000 dilution of mouse ascites of antibody 1H4, (kindly do- 
nated by Dr. A. Boyd, Melbourne, Australia),  followed  by 10 #g/ml 
goat antibody specific for mouse immunoglobulin (Ig) coupled to 
FITC (Southern Biotechnology  Associates, Birmingham, AL). Al- 
ternatively cells were stained for the expression of ELAM-1 an- 
tigen with a 1:3000 dilution of ammonium sulphate precipitated 
ascites containing mouse antibody H18/7 (generously provided by 
Drs. M. Munro and M. Gimbrone, Boston, MA) and then the 
goat anti-mouse Ig FITC detection reagent. All cell groups were 
also stained with second layer reagent alone (goat anti-mouse Ig 
FITC). Control staining was performed with 100 ~1 culture super- 
natant from HB55 cells (American  Tissue  Culture Collection, Rock- 
ville, MD) containing antibody specific for HLA-DR class II an- 
tigen or a control mouse IgG2a FITC reagent (Becton Dickinson 
and Co.) used at 10/~g/ml. All staining was performed on ice in 
the presence of  0.02% sodium azide. Fluorescence  analysis  was per- 
formed  by FACSCAN  (Becton-Dickinson  and Co., Mountain View, 
CA) and data is presented in the form of FACSCAN profiles (Fig. 
1 B and C; fluorescent intensity, x axis versus cell number, y axis) 
or as mean fluorescence  intensity values. 
Cytokine Assays.  Endothelial  cell culture supernatants  were har- 
vested after overnight culture, filtered to eliminate platelet or en- 
dothelial cell contamination and either used immediately or frozen 
until used in the bioassays  described  below. IL-6  was measured  using 
the B9 bybridoma  cell  line kindly provided  by Dr. L. Aarden. Briefly, 
2,000 B9 cells were cultured with either recombinant Ib6 (gener- 
ously provided by Interpharm Laboratories, Israel; specific  activity 
5.65  x  10  + U/rag) or 2- or 3-fold fold serial dilutions of the en- 
dothelial supernatants described above in triplicate wells to give 
a final volume of 200/~1 in RPMI-1640 with 10% FCS. After 3 
d incubation at 37~  the cells were pulsed with 0.5 #Ci tritiated 
thymidine (3H-thymidine) for the final 4 h of culture, harvested 
using a multi-well cell harvester (Skatron), and counted using a 
beta-plate system  (Pharmacia, UK). The standard  deviation  of mean 
counts from triplicate wells rarely exceeded 10%. GM-CSF was 
assessed in an assay utilizing cells kindly provided by Genetics In- 
stitute, Boston, MA and with help from Dr. C. Haworth (Chafing 
Cross Sunley Research Centre, London, UK).  Briefly, 2  x  104 
MO7-E cells were cultured for 3 d with endothelial derived super- 
natant or rGM-CSF (a kind gift of Dr. A. Krumwich, Behring- 
werke AG, Marburg; specific activity 4.5  x  107 CFU/mg) and 
measured for growth by incorporation of [3H]thymidine during 
the last 6 h of culture. Data for both Ib6 and GM-CSF activity 
measurements are presented as units per ml of cytokine activity 
where the values of a minimum of 2, and up to 6, serial dilutions 
of endothelial supernatant were computed from a standard curve 
of recombinant cytokine and these values presented as the mean 
U/ml  _+  SD. Specificity  of the bioactivity present in endothelial 
culture supernatants was ascertained  by the addition of neutralising 
antibodies specific  for IL-6 (goat anti-human IL-6, kindly provided 
by Dr. L. Aarden) and GM-CSF (rabbit antiserum generated by 
Drs. C. Haworth and E. Abney at Chafing Cross Sunley Research 
Centre, London, UK),  respectively. 
Results and Discussion 
Selective Induction of Adhesion Molecules on Endothelial Cells 
by Platelet-Derived ILl.  ICAM-1 is important for the adhe- 
sion of lymphocytes and monocytes to endothelium and its 
expression  is upregulated both in vivo and in vitro on en- 
dothelial cells by recombinant (r)Ibl (5, 14). In the current 
experiments, and as previously reported, both human umbil- 
ical vein (HUVEC) and adult saphenous vein (SAVEC) en- 
dothelial cell  monolayers responded to rib1  by enhanced 
1CAM-1 expression  (Fig.  1 B and C), as measured by FAC- 
SCAN analysis of specific binding of mAb 1H4. Thrombin 
activated  platdets,  when  used  to  stimulate  HUVEC  or 
SAVEC, also induced a significant increase in surface ICAM-1 
antigen expression.  No significant difference  was observed 
in the capacity of HUVEC or SAVEC to respond to platdets 
for enhanced ICAM-1 expression. Indeed while HUVEC are 
the most widely used modal of endothelium, there may be 
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differences due to their foetal nature and for this purpose the 
two cell types were therefore compared throughout. 
Our earlier data indicated that I1-1 was expressed predom- 
inantly by activated and not resting platelets (12). In the present 
study unstimulated platelets induced much lower increases 
in ICAM-1 expression on HUVEC (Fig. 2 A), although some 
variability was observed between experiments. In 7 experi- 
ments the fluorescent intensity (~  +  SE of the mean) of 
staining for ICAM-1 on unactivated HUVEC was 33  _+ 27, 
on cytokine induced HUVEC 198  _  91, on HUVEC cul- 
tured with resting platelets 58  _+  27 or activated platelets 
149  +_ 42. Supernatants from activated platelets did not in- 
crease ICAM-1 expression on HUVEC, demonstrating a re- 
quirement for a membrane associated function expressed on 
activated platelets (Fig.  2 A). Finally, platelet agonists such 
as thrombin failed to stimulate ICAM-1 expression (Fig.  2 
A) or influence ICAM-1 induction by rlL,1 (data not shown). 
A similar pattern of responsiveness was observed with SAVEC. 
Earlier studies calculated that 1.8  x  107 platelets induced 
a response comparable to 1 U/ml rlL-1 in the D10.G4.1 func- 
tional assay for IL-1 (12). This agrees with the estimate made 
in the present study, where activated platelets were compared 
with rI1-1 for the capacity to enhance ICAM-1 antigen ex- 
pression (Fig.  2 A). However this is a rough estimate since 
variation between platelet samples from different individuals 
was regularly observed (data not shown). This is in line with 
recent studies demonstrating similar individual variation in 
I1-1 production by peripheral blood derived monocytes from 
different donors (15). 
To determine whether IL-1 or other platelet derived prod- 
ucts mediated ICAM-1  induction, activated platelets were 
pretreated with antibodies to I1-1ol and IL-13 before stimu- 
lation  of HUVEC  or SAVEC.  The combination of both 
anti-I1-1 antibodies completely abrogated the capacity of ac- 
tivated platelets to increase HUVEC ICAM-1 levels above 
background (Fig.  2 B). A control antibody specific for IL-4 
had no significant effect (Fig. 2 B), and in additional experi- 
ments normal rabbit antiserum or antibodies to II-6 and TNF 
had no inhibitory effect on platelet induced ICAM-1 expres- 
sion. Similar results were obtained with SAVEC (Fig.  1 C). 
The requirement for antisera to both IL-lo~ and I1-13 to ob- 
tain significant inhibition of platelet stimulated endothelial 
function was confirmed by the failure to obtain good inhibi- 
tion with either alone (Fig.  2 B), and by titrating one anti- 
body in the presence of a fixed concentration of the second 
(data not shown), and represents data reproduced with an- 
tisera from two separate sources (Fig.  1 C versus 2 B). This 
Figure 1.  Activated platelets enhance  ICAM-1 antigen expression by 
human endothelial cells. Analysis of HUVEC (.4 and B) or SAVEC (C) 
stained: with control second layer reagent alone or for ICAM-1 expression 
on endothelial cells cultured overnight with medium, with rtbl, with 
thrombin activated platelets or thrombin activated platelets pretreated with 
anti-IL-1  antibody as described in Materials and Methods. Fluorescence 
analysis was performed by FACSCAN (Becton-Dickinson and Co.) and 
data is presented in the form of FACSCAN profiles (B and C: fluorescent 
intensity, x axis versus cell number, y axis). (A) demonstrates the purity 
of endothelial preparations. 
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Table  1.  Activated Platelets Selectively Modulate Adhesion 
Molecule Expression by Cultured Endothelial Cells 
Endothelial cell 
Mean fluorescent intensity 
expression of 
Source  Stimulus  ELAM-1  ICAM-1 
HUVEC 
SAVEC 
Medium 
IL-1 
Activated 
platelets 
Medium 
IL-1 
Activated 
platelets 
(n  =  1I)  (n  =  13) 
5.1  +  1.6  27.8  _+  2.2 
47.5  +  18.9  195.3  _+  98.1 
5.9  _+ 3.0  102.3  _+ 67.0 
(n  =3)  (n=  3) 
5.7  _+  1.1  19.5  _+  7.8 
57.8  _+ 8.8  126.3  +  23.9 
27.5  _+ 9.8  60.1  _+ 9.7 
HUVEC or SAVEC were cultured with medium, 1-100 ng/ml rlL-1B 
or 2  x  10; thrombin activated  platelets  for 6-8 h, at which time they 
were stained for the expression  of ELAM-1 antigen and ICAM-1 anti- 
gen as described in Materials  and  Methods. 
Figure 2.  Activated platelets induce  ICAM-1 expression on HUVEC 
in an IL-1 dependent  manner.  Endothelial  cells were cultured with either 
2  ￿  107 resting  or activated  platelets,  platelet  supernatants,  thrombin, 
the indicated  concentrations  (in U/ml) of rlL-1/7, or medium alone for 
20 h at 37~  in a 5% CO2 humidified  atmosphere.  In Fig. 2 B, 2  x 
10  ~ thrombin activated platelets  were pretreated  with medium alone or 
polyclonal rabbit antiserum  specific for IL-la, IblB, or a combination of 
both, or polyclonal rabbit  antiserum  specific for IL-4 before addition  to 
confluent endothelial monolayers. HUVEC were then stained as described 
in Materials and Methods  for ICAM-1 antigen expression (hatched bars). 
Control staining  was performed for HLA-DR (Fig. 2 A; clear bars), or 
a control mouse IgG2a FITC reagent (Fig. 2 B; clear bars) and second layer 
reagent  alone (control,  Fig. 2 A  and B; solid bars). Data are presented  as 
mean  fluorescent  intensity staining  evaluated by FACSCAN. 
was surprising since earlier studies measuring platelet derived 
II.-1 activity in the D10.G4.1 T  cell growth assay observed 
that mAbs specific for IL-lo~ and IL-13 inhibited 10-20% and 
80-90% ofplatelet activity, respectively (12). The reason for 
this difference is unclear, but is most readily explained by 
differences in the antibody preparations themselves. 
Plans to complete this study by showing the capacity of 
activated platelets to induce expression of a second IL-1 in- 
ducible adhesion molecule ELAM-1 (16),  uncovered a sur- 
prising difference between HUVEC and SAVEC. Although 
SAVEC responded to activated platelets by the upregulation 
of ELAM-1 antigen in an IL-1 dependent manner, HUVEC 
selectively failed to upregulate the ELAM-1 antigen, as demon- 
strated in Table 1, despite clear enhancement of ICAM-1 mea- 
sured in the same assays. The reason for this selectivity does 
not appear to represent presentation of insuf~cient IL-1 to 
HUVEC since increasing platelet number had no effect, nor 
was there any difference in the concentration of rlL-1 required 
to  induce ELAM-1  or  ICAM-1  expression  on  the  same 
HUVEC population (data not shown). This suggests heter- 
ogeneity of function of endothelial cells derived from different 
sources and may represent differential sensitivity to other 
platelet products (inhibiting ELAM-1 induction in HUVEC 
but not SAVEC) which is currently under investigation. 
Platelet-Derived ILl Stimulates Secretion of Cytokines by Cul- 
turedEndothelial Cells.  The addition of purified rlL-1 in vitro 
stimulates the release of a number of chemotactic and cytokine 
activities by endothelial cells (5, 6). To test whether platelets 
modulated other parameters of endothelial IL-1 inducible func- 
tion, secretion of IL-6 and granulocyte macrophage colony- 
stimulating factor (GM-CSF) by endothelial cells was assessed 
following stimulation with activated platelets. Fig. 3 A  and 
C demonstrate that activated platelets induced significant levels 
of bioactive II.,6 and GM-CSF production by HUVEC fol- 
lowing 1 day of coculture as measured in the B9 and MO7E 
bioassays, respectively. The activity of supernatants derived 
from endothelial cells cultured with activated platelets and 
testing positive in IL-6 and GM-CSF bioassays were neutral- 
ized by addition of anti-IL-6 or anti-GM-CSF antibodies to 
the appropriate bioassay. Resting platelets induced significant 
but lower levels of these cytokines as demonstrated in both 
the GM-CSF and IL-6 bioassay data in Fig. 3 A  and C. As 
predicted from the membrane bound nature of platelet IL-1, 
in all experiments performed supernatant derived from acti- 
vated platelets had no cytokine inducing capacity. Superna- 
tants derived from platelets cultured alone, in the absence 
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Figure 3.  Platelet derived ILl stimulates secretion of the cytokines IL-6 and GM-CSF by cultured endothelial cells. (,4 and C) HUVEC were cultured 
with the indicated numbers of resting (Rest.Pl.) or activated platelets (Act.PI.),  platelet supernatant from an equivalent number of thrombin activated 
platelets (Act.PI.SN),  thrombin, 20 ng/ml rlL-1B, or medium alone for 24 hours to measure GM-CSF  and II-6  secretion as described in Materials 
and Methods.  (B and D) SAVEC were cultured for 24 h with 10 ng/ml ri1r  or 2  x  107 thrombin  activated platelets which had been pretreated 
with irrelevant or anti-It,1 antibodies and supernatants tested in the cytokine bioassays. Data is presented as mean U/m] of cytokine activity +_  SD. 
Specificity of GM-CSF  activity in endothelial  cell (EC) culture supernatants was tested in the presence of specific antibody (.~ cpm  •  SD):  EC  + 
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of endothelial cells, failed to give a response in the cytokine 
assays (data not shown) demonstrating that secretion was due 
to endothelial cell activation.  Activated platelets were also 
able to induce production of GM-CSF and IL-6 by adult human 
saphenous  vein  endothelial  cells,  and  this  response  was 
abrogated by pretreatment of platelets with neutralizing an- 
tibodies to IL-lo~ and IL-1B, but not by irrelevant antibodies 
(Fig.  3 B  and D). 
The results presented in this paper demonstrate that acti- 
vated ptatelets are potent stimulators of endothelial cells de- 
rived from both umbilical cord vein and adult saphenous vein 
for the increased expression of the adhesion molecule ICAM-1, 
and production of the cytokines IL-6 and GM-CSF. This is 
due to the expression of surface bound IL-1 activity since en- 
hancement of ICAM-1 antigen and IL6 and GM-CSF produc- 
tion could  be  abrogated  by  the pretreatment  of activated 
platelets with antibodies specific  for IL-1, but not irrelevant 
ones.  Resting platelets were much weaker inducers  of en- 
dothelial IL-1 inducible function. It is noteworthy that resting 
platelets frequently stimulated significant endothelial responses, 
particularly  with respect to cytokine production. In this re- 
spect however, since no attempt was made to maintain un- 
stimulated platelets in a resting condition it is probable that 
coculture with endothelial cells in itself induced  some de- 
gree of platelet activation.  Finally neither supernatant derived 
from thrombin activated platelets or thrombin itself induced 
responses from the cultured endothelial cells. This is in agree- 
ment with our previously published data that platelet IL-1 
bioactivity is present in a ceU associated, but not secreted from, 
and  on activated  rather  than unstimulated  platelets  (12). 
Failure to stimulate expression of the IL-1 inducible adhe- 
sion molecule ELAM-1 on HUVEC, but not SAVEC, demon- 
strated a surprising heterogeneity in the function of endothelial 
cells derived  from different sources,  pointing  perhaps  to a 
selective capacity of platelets to modulate endothelial cell func- 
tion. A recent immunohistological study, supporting the con- 
cept of heterogeneous expression of ELAM-1 by different en- 
dothelia, demonstrates that vascular expression of ELAM-1 
occurs at cutaneous sites rather than noncutaneous ones (17). 
Following activation, platelets express or release a variety 
of mediators in addition to IL-1 including transforming growth 
factor  beta,  thrombospondin,  ~2  thromboglobulin,  and 
789  Hawrylowicz et al. platelet factor 4 (18-21). These may variously suppress or en- 
hance the response of endothelial cells to cytokines and a pos- 
sible role for selective downregulation of ELAM-1 but not 
ICAM-1 on HUVEC by other platelet products is currently 
under investigation. It is also likely that platelet products other 
than II-1 are also involved in enhancing endothelial cell stim- 
ulation by platelet derived I1-1, since on occasion activated 
platelets stimulated as high or higher levels of  cytokine  produc- 
tion than optimal concentrations of exogenous riD1. Neverthe- 
less, although other products may enhance the effects of  platelet 
delivered  I1:1 with  respect  to  endothelial production  of 
cytokines (or perhaps downregulate the expected expression 
of ELAM-1), it is clear that these platelet induced responses 
necessarily involve the expression of I1-1 since they are com- 
pletely inhibited in the presence  of anti-I1,1ot and fl anti- 
bodies (Fig.  2 B and 3 B  and D). 
These data support our original hypothesis that platelets 
may provide an important initiating signal for the inflamma- 
tory response via their expression and delivery of Ibl to vas- 
cular endothelial cells following injury. Platelets are ideally 
suited for such a role since they are targeted to local sites 
of endothelial injury, act quickly by expressing II:1 within 
minutes of activation and deliver a localised signal, as all platelet 
delivered I1:1 appears membrane associated.  Thus in addi- 
tion to their crucial role in haemostasis,  platelets may also 
be important in regulating inflammatory functions of the vas- 
cular endothelium, and may conceivably affect other cells with 
which they interact (for example monocytes, neutrophils, 
fibroblasts  and  smooth  muscle),  via  their  expression  of 
proinflammatory cytokines such as I1.-1. The demonstration 
that platelet derived I1:1 has functional consequences on vas- 
cular endothelium adds to the growing body of data im- 
plicating  platelets  as  critical  inflammatory  components 
(22, 23). 
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